HomeNewsaustedo, copaxone, fremanezumab, laquinimod, migraine, ms, multiple sclerosis, pridopidineTeva to Present New Data Across Multiple NS Therapeutic Areas at AAN

Teva to Present New Data Across Multiple NS Therapeutic Areas at AAN

  • April 18, 2018
  • Posted by: PharmaScroll
  • Category:
No Comments

Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced 38 scientific abstracts across five difficult-to-treat disorders of the central nervous system will be presented at the 70th Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles from April 21-27, 2018. The breadth of data spans a diverse set of patient populations including migraine, multiple sclerosis, tardive dyskinesia and Huntington’s disease.

“Teva’s data at AAN embodies our expertise in researching and developing highly complex treatments for CNS disorders, especially those for which there is still an enormous unmet patient need,” said Tushar Shah, M.D., Senior Vice President, Head of Specialty Clinical Development and Medical Affairs at Teva. “Our ongoing research reflects Teva’s goal of developing innovative therapeutic solutions that aim to help enable people to live better days.”

Among the 21 accepted migraine abstracts to be presented, 19 include additional data from the Phase III HALO clinical trial program for fremanezumab, a monoclonal antibody targeting the CGRP (calcitonin gene-related peptide) ligand, currently being investigated as a preventive treatment for migraine. These data examined the overall efficacy, safety and tolerability profile of fremanezumab in both chronic and episodic migraine. Studies included patients on fremanezumab alone or in combination with other preventive medications.

Additional data further contribute to the scientific understanding of the efficacy, safety and tolerability of Teva’s COPAXONE® (glatiramer acetate injection) for the treatment of relapsing multiple sclerosis (RMS), including up to seven-year results from the Glatiramer Acetate Low-Frequency Administration (GALA) study and an abstract assessing pregnancy outcomes in RMS patients exposed to COPAXONE® 20 mg/mL during all three trimesters. Teva will also present AUSTEDO® (deutetrabenazine) tablets data providing clinical and real-world insights into the applicability of use across chorea associated with Huntington’s disease and tardive dyskinesia in adults, two often underserved and overlooked movement disorders.

The full set of Teva-sponsored data to be presented includes:

Fremanezumab:

  • [S32.005] Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (Platform Session 32, April 25, 2018, 1:00 – 3:00 p.m. PT)
  • [S32.007] The Impact of Fremanezumab on Work Productivity and Activity Impairment in Patients with Chronic Migraine (Platform Session 32, April 25, 2018, 1:00 – 3:00 p.m. PT)
  • [P3.139] The Impact of Headache Free Days on Quality of Life and Costs Among People with Migraine with >4 Headache Days in the Past Month (Poster Session 3, April 24, 2018, 11:30 – 7:00 p.m. PT)
  • [P3.144] Burden of Illness Among Treated Migraine Patients with ≥4 Headache Days in the Past Month (Poster Session 3, April 24, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.093] Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine(Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.095] The Impact of Fremanezumab on Headache-Related Disability in Patients with Episodic Migraine using the Migraine Disability Assessment (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.097] Efficacy of Fremanezumab in Patients With Chronic Migraine and Comorbid Moderate to Moderately Severe Depression (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.099] Efficacy of Fremanezumab in Patients With Chronic Migraine With or Without Concomitant Use of Preventive Medication (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.101] Impact of Fremanezumab on the Number of Days with Use of Acute Headache Medications in Chronic Migraine (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.102] Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.104] Efficacy of Fremanezumab in Patients With Chronic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.106] Impact of Fremanezumab on the Number of Days With Use of Acute Headache Medications in Episodic Migraine (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.107] Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.109] The Impact of Fremanezumab on Headache-Related Disability in Patients with Chronic Migraine Using the Headache Impact Test (HIT-6) (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.110] Efficacy of Fremanezumab in Patients With Episodic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.111] Fremanezumab for Decreasing Migraine Symptoms such as Nausea, Vomiting, Photophobia and Phonophobia and Reducing the Need for Acute Medications in the First Week of Treatment in the HFEM Study (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.112] Reversion of Patients With Chronic Migraine to an Episodic Migraine Classification With Fremanezumab Treatment (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.113] Response with Fremanezumab in the Treatment of Chronic Migraine (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.114] Fremanezumab for Reducing Headache Pain within the First Week of Beginning Treatment in the Phase 2 Episodic Migraine Study (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.115] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.117] The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life and Overall Health Status in Chronic Migraine (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)

COPAXONE®:

  • [P1.370] Integrated Transcriptomic and Physicochemical Characterization of Glatiramer Acetate Products (Copaxone and Glatopa) Available in the United States (Poster Session 1, April 22, 2018, 11:30 – 5:30 p.m. PT)
  • [P1.400] Physicochemical and Biological Characterization of both Copaxone and the European Follow-On Glatiramer Acetate Product (Poster Session 1, April 22, 2018, 11:30 – 5:30 p.m. PT)
  • [P3.415] Defining Glatiramer Acetate: The USA Definition of Sameness and the EU Definition of Similarity (Poster Session 3, April 24, 2018, 11:30 – 7:00 p.m. PT)
  • [P3.416] Bayesian Analysis of Glatiramer Acetate 40 mg/mL TIW Treatment Effect in Reducing Relapse Rate (Poster Session 3, April 24, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.362] Pregnancy Outcomes in Patients with Multiple Sclerosis and Exposure to Branded Glatiramer Acetate During all Three Trimesters (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P6.378] Long-term Efficacy, Safety, and Tolerability of Three-times Weekly Dosing Regimen of Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis Patients: 5-year Results of the Glatiramer Acetate Low-Frequency Administration (GALA) Open-label Extension Study (Poster Session 6, April 27, 2018, 11:30 – 5:30 p.m. PT)

AUSTEDO®:

  • [P4.040] Initial Deutetrabenazine Compliance, Satisfaction, and Patient Perception of Change in Huntington Disease Symptoms (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.044] Healthcare Utilization and Costs for Huntington Disease Patients Prescribed Tetrabenazine (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.050] Experience of Individuals With Huntington Disease and Chorea (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.075] Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.076] Long-Term Treatment With Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study(Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.077] Effect of Tardive Dyskinesia on Quality of Life: Patient-reported Symptom Severity is Associated with Deficits in Physical, Mental, and Social Functioning (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.080] Cardiovascular Safety Assessment of Deutetrabenazine in Healthy Volunteersand Implications for Patients With Huntington Disease or Tardive Dyskinesia (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.081] Tardive Dyskinesia Among Patients Using Antipsychotic Medications in Customary Clinical Care in the United States (Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)

Laquinimod:

  • [S8.003] ARPEGGIO: A Placebo-controlled Trial of Oral Laquinimod in Primary Progressive Multiple Sclerosis (Platform Session 8, April 22, 2018, 3:30 – 5:30 p.m. PT)

Pridopidine:

  • [P3.324] Pridopidine Treatment Recovers Gait Abnormalities and Rescues Impaired BDNF Expression in a Rett Syndrome Mouse Model (Poster Session 3, April 24, 2018, 11:30 – 7:00 p.m. PT)
  • [P4.048] Loss of the Sigma-1 Receptor Disrupts Pridopidine-induced Gene Expression(Poster Session 4, April 25, 2018, 11:30 – 7:00 p.m. PT)

 

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/

 

News Source: Teva Website

Image Source: https://www.fiercepharma.com/legal/embattled-teva-sues-former-regulatory-exec-for-theft-trade-secrets